Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

NCT07286032 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT07286032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07286032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
April 16, 2026
Completion date
June 30, 2029
Enrollment
150 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

patients with chemotherapy-induced thrombocytopenia